119 related articles for article (PubMed ID: 29066722)
21. Bcl-XL mediates epidermal growth factor dependent cell survival in HC11 mammary epithelial cells.
Romorini L; Coso OA; Pecci A
Biochim Biophys Acta; 2009 Mar; 1793(3):496-505. PubMed ID: 19121340
[TBL] [Abstract][Full Text] [Related]
22. A cytoskeleton-based functional genetic screen identifies Bcl-xL as an enhancer of metastasis, but not primary tumor growth.
Martin SS; Ridgeway AG; Pinkas J; Lu Y; Reginato MJ; Koh EY; Michelman M; Daley GQ; Brugge JS; Leder P
Oncogene; 2004 Jun; 23(26):4641-5. PubMed ID: 15064711
[TBL] [Abstract][Full Text] [Related]
23. Bcl-xL mediates therapeutic resistance of a mesenchymal breast cancer cell subpopulation.
Keitel U; Scheel A; Thomale J; Halpape R; Kaulfuß S; Scheel C; Dobbelstein M
Oncotarget; 2014 Dec; 5(23):11778-91. PubMed ID: 25473892
[TBL] [Abstract][Full Text] [Related]
24. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
Wang Y; Niu XL; Qu Y; Wu J; Zhu YQ; Sun WJ; Li LZ
Cancer Lett; 2010 Sep; 295(1):110-23. PubMed ID: 20236757
[TBL] [Abstract][Full Text] [Related]
25. Distinct apoptotic blocks mediate resistance to panHER inhibitors in HER2+ breast cancer cells.
Karakas B; Ozmay Y; Basaga H; Gul O; Kutuk O
Biochim Biophys Acta Mol Cell Res; 2018 Aug; 1865(8):1073-1087. PubMed ID: 29733883
[TBL] [Abstract][Full Text] [Related]
26. Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer.
Jin J; Xiong Y; Cen B
Anticancer Drugs; 2017 Nov; 28(10):1141-1149. PubMed ID: 28885267
[TBL] [Abstract][Full Text] [Related]
27. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
28. HOXC8 regulates self-renewal, differentiation and transformation of breast cancer stem cells.
Shah M; Cardenas R; Wang B; Persson J; Mongan NP; Grabowska A; Allegrucci C
Mol Cancer; 2017 Feb; 16(1):38. PubMed ID: 28202042
[TBL] [Abstract][Full Text] [Related]
29. Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3.
Zannetti A; Iommelli F; Fonti R; Papaccioli A; Sommella J; Lettieri A; Pirozzi G; Bianco R; Tortora G; Salvatore M; Del Vecchio S
Clin Cancer Res; 2008 Aug; 14(16):5209-19. PubMed ID: 18698039
[TBL] [Abstract][Full Text] [Related]
30. Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak.
Castilla C; Congregado B; Chinchón D; Torrubia FJ; Japón MA; Sáez C
Endocrinology; 2006 Oct; 147(10):4960-7. PubMed ID: 16794010
[TBL] [Abstract][Full Text] [Related]
31. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
Henkels KM; Turchi JJ
Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248
[TBL] [Abstract][Full Text] [Related]
32. NF-κB activation fails to protect cells to TNFα-induced apoptosis in the absence of Bcl-xL, but not Mcl-1, Bcl-2 or Bcl-w.
Casanelles E; Gozzelino R; Marqués-Fernández F; Iglesias-Guimarais V; Garcia-Belinchón M; Sánchez-Osuna M; Solé C; Moubarak RS; Comella JX; Yuste VJ
Biochim Biophys Acta; 2013 May; 1833(5):1085-95. PubMed ID: 23369735
[TBL] [Abstract][Full Text] [Related]
33. Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells.
Arisan ED; Kutuk O; Tezil T; Bodur C; Telci D; Basaga H
Breast Cancer Res Treat; 2010 Jan; 119(2):271-81. PubMed ID: 19238538
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of Bcl-xL in human breast cancer cells enhances organ-selective lymph node metastasis.
España L; Fernández Y; Rubio N; Torregrosa A; Blanco J; Sierra A
Breast Cancer Res Treat; 2004 Sep; 87(1):33-44. PubMed ID: 15377849
[TBL] [Abstract][Full Text] [Related]
35. Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer.
Mu P; Nagahara S; Makita N; Tarumi Y; Kadomatsu K; Takei Y
Int J Cancer; 2009 Dec; 125(12):2978-90. PubMed ID: 19422046
[TBL] [Abstract][Full Text] [Related]
36. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
37. The N-terminus and alpha-5, alpha-6 helices of the pro-apoptotic protein Bax, modulate functional interactions with the anti-apoptotic protein Bcl-xL.
Parikh N; Koshy C; Dhayabaran V; Perumalsamy LR; Sowdhamini R; Sarin A
BMC Cell Biol; 2007 May; 8():16. PubMed ID: 17519046
[TBL] [Abstract][Full Text] [Related]
38. A targeted proteomics approach to the quantitative analysis of ERK/Bcl-2-mediated anti-apoptosis and multi-drug resistance in breast cancer.
Yang T; Xu F; Sheng Y; Zhang W; Chen Y
Anal Bioanal Chem; 2016 Oct; 408(26):7491-503. PubMed ID: 27510278
[TBL] [Abstract][Full Text] [Related]
39. Fractalkine/CX3CR1 induces apoptosis resistance and proliferation through the activation of the AKT/NF-κB cascade in pancreatic cancer cells.
Wang H; Cai J; Du S; Guo Z; Xin B; Wang J; Wei W; Shen X
Cell Biochem Funct; 2017 Aug; 35(6):315-326. PubMed ID: 28845524
[TBL] [Abstract][Full Text] [Related]
40. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis.
Liu JR; Fletcher B; Page C; Hu C; Nunez G; Baker V
Gynecol Oncol; 1998 Sep; 70(3):398-403. PubMed ID: 9790794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
